![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euroapi-corp-ad-w30-desktop-header-1-2gif-57087.gif)
![Euroapi Company Header](https://www.pharmacompass.com/image/flap/euro-api-mob-header-w30gif-19381.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
S-217622 (ensitrelvir fumaric acid), an antiviral drug for COVID-19 currently approved under the emergency regulatory approval system in Japan, is a 3CL protease inhibitor. Ensitrelvir suppresses the replication of SARS-CoV-2 by selectively inhibiting 3CL protease.
Lead Product(s): Ensitrelvir Fumaric Acid
Therapeutic Area: Infections and Infectious Diseases Product Name: S-217622
Highest Development Status: Phase IIIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Chia Tai Tianqing Pharmaceutical Group
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement December 29, 2022